Intraductal tubulopapillary neoplasms of the bile ducts: Clinicopathologic, immunohistochemical, and molecular analysis of 20 cases Journal Article


Authors: Schlitter, A. M.; Jang, K. T.; Klöppel, G.; Saka, B.; Hong, S. M.; Choi, H.; Offerhaus, G. J.; Hruban, R. H.; Zen, Y.; Konukiewitz, B.; Regel, I.; Allgäuer, M.; Balci, S.; Basturk, O.; Reid, M. D.; Esposito, I.; Adsay, V.
Article Title: Intraductal tubulopapillary neoplasms of the bile ducts: Clinicopathologic, immunohistochemical, and molecular analysis of 20 cases
Abstract: Intraductal tubulopapillary neoplasm is a well-established entity in the pancreas. A similar, if not identical, tumor occurs also in the biliary tract. We conducted a multicenter study of 20 such lesions, focusing on their clinicopathologic characteristics and molecular profile. Biliary intraductal tubulopapillary neoplasms were seen in patients in their 60s (mean 62 years). The tumors were intrahepatic 70%, extrahepatic 10%, and perihilar 20%; mean tumor size was 6.9 cm. Histologically, all intraductal tubulopapillary neoplasms showed, in addition to their typical tubular pattern, solid areas (70%) or abortive papillae (50%). Necrosis was common (85%), predominantly focal (40%), and with 'comedocarcinoma-like pattern' in 40%. Immunohistochemically, these neoplasms were characterized by the expression of MUC1 (80%) and MUC6 (30%) and by the absence of MUC2 and MUC5AC. Associated invasive carcinomas were present in 16 (80%), mainly conventional tubular adenocarcinoma (50%). The molecular alterations observed included CDKN2A/p16 (intraductal components 44%, invasive 33%) and TP53 (intraductal components 17%, invasive 9%). Mutations in KRAS (intraductal 6%, invasive 0%), PIK3CA (intraductal 6%, invasive 0%), and loss of SMAD4/DPC4 (intraductal 7%, invasive 0%) were rare. No alterations/mutations were identified in IDH1/2, BRAF, GNAS, EGFR, HER2, and β-catenin. Follow-up information was available for 17 patients (85%) with mean follow-up 44 months. Overall combined survival rates showed favorable prognosis: 1 year 100%, 3 years 90%, and 5 years 90%. In conclusion, despite the relatively high incidence of invasive carcinoma (80%), available follow-up suggests that biliary intraductal tubulopapillary neoplasms have an indolent behavior. Molecular analyses highlight the low prevalence of alterations of common oncogenic signaling pathways in intraductal tubulopapillary neoplasm. Further studies using whole-exome sequencing are required to discover yet unknown molecular changes and to understand the carcinogenesis of intraductal tubulopapillary neoplasms. © 2015 USCAP, Inc All rights reserved.
Keywords: immunohistochemistry; adult; cancer survival; clinical article; human tissue; protein expression; treatment outcome; aged; middle aged; cancer surgery; survival rate; gene mutation; overall survival; exon; follow up; lymph node metastasis; protein p16; epidermal growth factor receptor; epidermal growth factor receptor 2; weight reduction; cell differentiation; protein p53; carcinogenesis; abdominal pain; cancer size; cytoplasm; pancreas adenocarcinoma; jaundice; liver surgery; invasive carcinoma; bile duct carcinoma; cell nucleus; mucin 1; cyclin dependent kinase inhibitor 2a; k ras protein; beta catenin; b raf kinase; perineural invasion; bile duct cancer; transcription factor cdx2; mucin 5ac; mucin 2; mucin 6; isocitrate dehydrogenase 1; tumor necrosis; smad4 protein; multicenter study (topic); cancer prognosis; isocitrate dehydrogenase 2; phosphatidylinositol 4,5 bisphosphate 3 kinase; human; male; female; priority journal; article; hemihepatectomy; biliary intraductal tubulopapillary neoplasm
Journal Title: Modern Pathology
Volume: 28
Issue: 9
ISSN: 0893-3952
Publisher: Nature Research  
Date Published: 2015-09-01
Start Page: 1249
End Page: 1264
Language: English
DOI: 10.1038/modpathol.2015.61
PROVIDER: scopus
PUBMED: 26111977
DOI/URL:
Notes: Export Date: 2 October 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Olca Basturk
    352 Basturk